Psoriatic Arthritis

TNF vs Interleukin Inhibitors: Patient Characteristics, Treatment Persistence in Psoriatic Arthritis

Researchers compared patient characteristics and treatment persistence among patients with psoriatic arthritis who initiated tumor necrosis factor vs interleukin 12/23 or 17 inhibitors as first-line biologic treatment.

Inflammatory Bowel Disease Risk in Patients With PsA and AS Initiating Treatment With IL-17 Inhibitors

Researchers assessed the association between initiation with IL-17 inhibitors and risk for inflammatory bowel disease in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis

Factors Linked to Development of Pediatric Psoriasis Identified

Factors were independently linked to development include atopic dermatitis, family history of psoriasis, skin and fungal infections.

Secukinumab vs Adalimumab in Concomitant PsA and Plaque Psoriasis

Secukinumab vs adalimumab for treatment in patients with concomitant plaque psoriasis and active psoriatic arthritis during 52 weeks is reported.

Treatment With Biologics for Psoriasis Decreases Risk of Developing Psoriatic Arthritis

The objective of the study was to determine the risk of developing psoriatic arthritis in patients with psoriasis receiving certain treatments, such as biologics.

Identifying Novel Risk HLA Allotypes in Different Spondyloarthritis Subtypes

Researchers studied the HLA profile of patients with enthesitis and/or arthritis not fulfilling the ASAS criteria, with an emphasis on psoriatic arthritis and undifferentiated spondyloarthritis.

Risk for Total Hip and Knee Arthroplasty Not Reduced by NSAIDs, DMARDs, and/or TNF Inhibitors in Patients With PsA and AS

Researchers evaluated the risk for total hip and knee arthroplasty with regard to the use of NSAIDs, DMARDs, and TNF inhibitors in patients with psoriatic arthritis and ankylosing spondylitis.

Papers on COVID-19 in Psoriasis, Psoriatic Arthritis Carry Risk for Bias

Published papers addressing the risk and outcomes of COVID-19 in patients with psoriasis and psoriatic arthritis receiving biologic therapies have a high risk for bias.

Mortality Rates From Acute Myocardial Infarction Similar Among Patients With PsA and General Population

The objective of the study was to evaluate the trends for hospitalizations and inpatient mortality from acute myocardial infarction among patients with psoriatic arthritis.

Increased Risk for Major Adverse Cardiovascular Events Among Patients With PsA Receiving IL vs TNF Inhibitors

Researchers assessed the risk for major adverse cardiovascular events in patients with psoriatic arthritis receiving treatment with different classes of DMARDs.